SOX9在结直肠癌中的剂量依赖性效应及其发生率
SOX9是HMG结构域转录因子家族成员,在肠道上皮中表达并参与稳态维持。近期研究提示高水平SOX9与II期结直肠癌良好预后相关,但越来越多证据表明需考虑SOX9的剂量依赖性效应。鉴于SOX9在肠道上皮中作为抑癌基因还是癌基因存在反复争议且缺乏系统综述,本文对SOX9在肠道中的生物学功能及其在结直肠癌中作用的知识进行更新。
要点
- SOX9属于HMG结构域转录因子超家族,在肠道上皮中表达并参与稳态维持。
- 高水平SOX9近期被报道与II期结直肠癌良好预后相关。
- SOX9在肠道上皮中的功能需考虑其剂量依赖性效应。
核心结论
- SOX9在肠道上皮中的作用需考虑剂量依赖性效应,其在结直肠癌中作为抑癌基因或癌基因仍存争议,本文对相关生物学功能及作用进行知识更新。
研究设计与样本
- 本文为综述,旨在更新SOX9在肠道中的生物学功能及其在结直肠癌中作用的知识。
主要发现
- SOX9在包括肠道上皮在内的多种组织中表达,目前被认为对稳态维持具有重要作用。
- 近期研究将高水平SOX9与II期结直肠癌的良好预后相关。
- 越来越多证据表明,解读SOX9在肠道中的功能必须考虑其剂量依赖性效应。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A member of the Sry-related HMG-box family of transcription factors (SOX9) is a transcription factor that belongs to the superfamily of High Mobility Group (HMG) domain transcription factors. SOX9 is expressed in a variety of tissues, including as the intestinal epithelium, where it is now recognised as an important actor for homeostasis. Beside, a high level of SOX9 has recently been correlated with a good prognosis for stage II colorectal cancers. However, growing evidence indicates that deciphering the function of SOX9 in the intestine has to take into account a dose-dependent effect of SOX9. Given the recurrent controversies and the lack of a state of the art as to whether SOX9 behaves like a tumour suppressor or an oncogen in the intestine epithelium, it is time to provide an update of the accumulated knowledge about the biological function of SOX9 in the intestine and about the role of SOX9 in colorectal cancers.
引用
- Prévostel C, Blache P. The dose-dependent effect of SOX9 and its incidence in colorectal cancer. Eur J Cancer. 2017. PMID: 28988015. doi:10.1016/j.ejca.2017.08.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。